Pharmaceutical
Medical Devices
Technology

Daiichi Sankyo

$40.54
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.03 (-0.07%) Today
-$0.03 (-0.07%) Today

Why Robinhood?

You can buy or sell Daiichi Sankyo and other stocks, options, ETFs, and crypto commission-free!

About

Daiichi Sankyo Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Daiichi Sankyo Group and Ranbaxy Group. Read More The Daiichi Sankyo Group segment comprises of Daiichi Sankyo Co., Ltd. and its subsidiaries. The Ranbaxy Group segment includes its core company, Ranbaxy Laboratories Ltd. Both group segments deal with business activities in prescription drugs and general pharmaceutical products. The company was founded on September 28, 2005 and is headquartered in Tokyo, Japan. DSNKY is listed on the Pink Current market tier. OTC market data is provided by OTC Markets Group, Inc (otcmarkets.com).

Employees
14,446
Headquarters
Tokyo, Tokyo
Founded
2005
Market Cap
26.28B
Price-Earnings Ratio
44.14
Dividend Yield
1.60
Average Volume
15.57K
High Today
$40.57
Low Today
$40.28
Open Price
$40.57
Volume
2.20K
52 Week High
$43.74
52 Week Low
$30.00

Collections

Pharmaceutical
Medical Devices
Technology
Health
Medical
Asia (Non-China)
Asia

News

PR Newswire6h

Data from the Non-interventional EMIT-AF/VTE Study Shows Low Thromboembolic and Bleeding Event Rates in Unselected Elderly AF/VTE Patients on Oral, Once-daily LIXIANA®▼ Undergoing Diagnostic or Therap

MUNICH, March 19, 2019 /PRNewswire/ -- In 2019, the Edoxaban Clinical Research Programme will deliver new evidence on LIXIANA ® ▼ (edoxaban) use in clinical practice. EMIT-AF/VTE is one of the first sets of data to be presented EMIT-AF/VTE is a large observational, multicentre, multinational study on edoxaban peri-procedural management and outcomes It is the first large prospective, non-interventional study to apply the European Heart Rhythm Association (EHRA) bleeding risk classification in edoxaban rou...

0
PR Newswire7h

CLEAR Wisdom Demonstrated First-in-class, Oral, Once-daily, ACL Inhibitor Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP

MUNICH and ANN ARBOR, Michigan, March 19, 2019 /PRNewswire/ -- Daiichi Sankyo Europe GMbH (hereafter, 'Daiichi Sankyo') and Esperion (NASDAQ: ESPR) today announced that the Phase 3 results from CLEAR Wisdom of first-in-class, oral, once-daily ATP citrate lyase (ACL) inhibitor, bempedoic acid, were presented at the ACC Scientific Sessions & Expo in New Orleans.

1
PR NewswireMar 18

Daiichi Sankyo Presents Positive Results of the First Randomised, Controlled Trial of Uninterrupted Oral, Once-daily LIXIANA®▼ (edoxaban) in Atrial Fibrillation Patients Undergoing Catheter Ablation

MUNICH, March 18, 2019 /PRNewswire/ -- ELIMINATE-AF is the first set of data presented in 2019 from the Edoxaban Clinical Research Programme, which will deliver new evidence to support the use of edoxaban in clinical practice Late-breaking data presented at EHRA 2019, the annual congress of the European Heart Rhythm Association, shows ELIMINATE-AF met primary efficacy and safety objectives, demonstrating low thromboembolic and bleeding event rates 1 ELIMINATE-AF provides evidence that uninterrupted LIXIA...

3
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.